The endothelium modulates vascular tone by releasing nitric oxide, which is a potent vasodilator and inhibitor of platelet aggregation. Together with prostacyclin, the endogenous nitrate nitric oxide has an important protective role in preventing vasospasm and thrombus formation. In addition, the endothelium is a source of contracting factors such as endothelin-1, thromboxane A 2 and endoperoxides. Due to its strategic anatomical position, the endothelium is a primary target for injurious stimuli and cardiovascular risk factors. Low density lipoproteins reduce endothelium-dependent relaxation and enhance endotheliumdependent contraction. The same pattern of endothelial dysfunction occurs in hypercholesterolaemia and atherosclerosis. These alterations of endothelial function may contribute to vasospasm, ischaemia and thrombus formation, which are common events in patients with atherosclerotic vascular disease.
Introduction
The endothelium is involved in the regulation of vascular tone. It releases relaxing and contracting factors under basal conditions and when activated by neurotransmitters, humoral mediators, autacoids or physical stimuli. 2 The production of these factors modulates vascular diameter and in turn local blood flow. 3 3 Due to its strategic anatomical position the endothelium is a target organ for hypertension, diabetes and hyperlipidaemia.4,5 A reduced release of endothelium-derived relaxing factors and an enhanced liberation of endotheliumderived contracting factors are observed under such conditions. These alterations in endothelial function are likely to contribute to the pathogenesis as well as the progression of cardiovas- Figure 1 Nitric oxide is formed from L-arginine. The endogenous nitrate causes = relaxation as well as inhibition of platelet aggregation by activating soluble guanylate cyclase in vascular smooth muscle cells as well as in platelets. This mechanism constitutes an important protective feature of the endothelium against vasospasm and thrombus formation. (Source: Luscher TF, Richard inhibits endothelium-dependent relaxations to the monoamine. L-arginine, but not D-arginine, restores the relaxation indicating that the former is the substrate for the production of nitric oxide and that L-NMMA is a competitive inhibitor of the aminoacid. ( Source: Richard Tanner FC, Tschudi This article describes the principles of endothelium-dependent vascular regulation and focuses on the dysfunction of these mechanisms occurring in hyperlipidaemia and atherosclerosis.
Endothelium-dependent vascular regulation
Endothelium-derived relaxing factors Endothelium-derived nitric oxide (ED NO) Endothelium-dependent relaxations occur in isolated blood vessels as well as in the intact organism. They are elicited by transmitters, hormones, substances derived from platelets and from the kinin system as well as by coagulation factors.2 Further, physical stimuli such as shear stress also promote endothelium-dependent vasodilatation. 6 The relaxations are related to the formation of endothelium-derived relaxing factor. Endothelium-derived relaxing factor is a diffusible substance with a half-life of some seconds.7
It is inactivated by superoxide and haemoglobin and is stabilized by superoxide dismutase.8,9
In endothelial cells in culture as well as the rabbit aorta, agonists such as bradykinin stimulate the release of nitric oxide (EDNO). 10
Since this radical has the same characteristics as described for endothelium-derived relaxing factor and is liberated in sufficient amounts to account for the vascular effect of the relaxing factor, it can be considered identical with the factor.11,12 However, debate still continues as to whether EDNO is released as authentic nitric oxide or as a nitrosylated compound such as S-nitrosocysteine. 13
The precursor for the formation of EDNO is Larginine ( Figure 1 ).14,15 Cultured endothelial cells depleted of L-arginine lose the capacity to release EDNO until the amino acid is reintroduced to the medium. In porcine coronary arteries, endothelium-dependent relaxations in response to serotonin are inhibited by L-NG-monomethyl arginine (L-NMMA) and are restored by Larginine, but not D-arginine ( Figure 2 ).16 When infused into rabbits, L-NMMA causes long lasting increases in blood pressure which are reversed by L-arginine. 17 Apart from L-NMMA, the L-arginine pathway can be blocked by several other L-arginine derivatives such as L-NG-nitro arginine methyl ester. 18 EDNO is formed by oxidation of the guanidino-nitrogen terminal of L-arginine ( Figure 3 ).15 The enzyme responsible for this reaction has been partially purified. It is a cytosolic enzyme requiring calmodulin, calcium and NADPH. 19 It not only occurs in endothelial cells, but also in platelets, macrophages, vascular smooth muscle cells and in the brain.2o-23 Relaxations in response to EDNO are associated with increases in the concentration of cyclic GMP in vascular smooth muscle cells. (Figure 1 ).24,25 The inhibitor of guanylate cyclase, methylene blue, prevents the production of cyclic GMP and inhibits endothelium-dependent relaxations. 26, 27 Thus EDNO causes relaxations by stimulating soluble guanylate cyclase leading to the formation of cyclic GMP in vascular smooth muscle cells. Soluble guanylate cyclase is also present in platelets and is activated by EDNO ( Figure 1 ). Increased levels of cyclic GMP are associated with a reduced adhesion and aggregation of platelets. 28,29 Therefore, EDNO induces both vasodilatation and inhibition of platelet activation ; not surprisingly its release is considered to be an important antithrombotic feature of the endothelium.
Prostacyclin
Prostacyclin is the major product of cyclooxygenase in the blood vessel wall (Figure 4 ). 30 The concentration of prostacyclin synthetase, the final enzyme for the synthesis of the prostaglandin, progressively decreases from the intima to the adventitia; thus, the endothelium is a major source of prostacyclin.31 Its production is stimulated by shear stress, hypoxia and many of the mediators which lead to the formation of EDNO. However, the contribution of prostacyclin to endothelium-dependent relaxations is small or even negligible.32 The relaxations are associated with an increase in cyclic AMP in vascular smooth muscle cells. 33 Prostacyclin is also involved in the inhibition of platelet aggregation ; this effect is related to the production of cyclic AMP in platelets Prostacyclin interacts with EDNO at several levels. It stimulates the release of EDNO and enhances the responsiveness of vascular smooth muscle to the factor. 34 Furthermore, in human platelets EDNO and prostacyclin are synergistic in inhibiting platelet aggregation in that a subthreshold concentration of the prostaglandin amplifies the effect of EDNO and vice versa. 34, 35 Other endothelium-derived relaxing factors (EDRF) The endothelium releases more than one relaxing factor (Figure 4 ).36 In porcine endothelial cells, ouabain inhibits the effects of the factor released by shear stress or ADP, but not that of the factor liberated by bradykinin or calcium ionophore A 23187.3~ In canine coronary arteries, ouabain prevents relaxations to the factor released by shear stress, but not that induced by bradykinin.38 In porcine coronary arteries, L-NMMA inhibits relaxations to serotonin, but not those to bradykinin.16 There are several possible candidates for these relaxing factors distinct from nitric oxide including a hyperpolarizing factor, or products of cyclo-oxygenase, lipoxygenase or the P 450 pathway. Acetylcholine not only causes an endotheliumdependent relaxation, but also an endotheliumdependent hyperpolarization of vascular smooth muscle which is mediated by a diffusible substance. However, the relaxation to the muscarinic agonist is sustained, while the hyperpolarization is transient. 39 Furthermore, the relaxation is inhibited by haemoglobin, but not ouabain, while the hyperpolarization is prevented by ouabain, but not haemoglobin.4~ Thus, an endotheliumdependent hyperpolarizing factor distinct from nitric oxide must be involved although the Figure 3 Hypothetical mechanism of the production of nitric oxide from L-arginine. Nitric oxide is cleaved from the guanidino nitrogen terminal of L-arginine, while the aminoacid is converted to L-citrulline. (Source: Marletta MA. Nitric oxide: biosynthesis and biological significance. Trends Biol Sci 1989; 14: 488-92.) latter was shown to have hyperpolarizing properties, at least under certain experimental conditions.41 The endothelium-derived hyperpolarizing factor activates ATP-sensitive potassium channels on vascular smooth muscle cells. 42 The hyperpolarization may contribute to endothelium-dependent relaxations or reduce the sensitivity of vascular smooth muscle to vasoconstrictor stimuli.
Prostaglandin E2 is a product of cyclooxygenase released in the coronary microcirculation contributing to hypoxic dilatation. 43, 44 The prostaglandin causes relaxation when added exogenously. Similar to prostacyclin, however, the relaxing effect of the substance is small. Moreover, the endogenous formation of products of cyclo-oxygenase is negligible, since indomethacin does not affect endothelium-dependent relaxations in many types of blood vessels. A similar pattern is obtained with products of lipoxygenase. Thus, products of cyclo-oxygenase as well as lipoxygenase do not play a major role in endothelium-dependent relaxation.
Endothelium-derived contracting factors Hypoxic endothelium-derived contracting factor (EDCFI) Under hypoxic conditions many types of vessels contract in an endothelium-dependent manner (Figure 5 ).45 The contractions cannot be attributed to a reduced release or an inhibited action of endothelium-derived relaxing factors. The mediator of the hypoxic response is still elusive, but must be related to the production of a diffusible endothelium-derived contracting factor.45 Calcium antagonists inhibit hypoxic contractions at the level of vascular smooth muscle. 46 Although endothelin is released during hypoxia Figure 4 The endothelium releases more than one relaxing factor in porcine coronary arteries. Alpha-2-adrenergic agonists such as clonidine release nitric oxide in both epicardial and intramyocardial porcine coronary arteries. The contribution of nitric oxide to endothelium-dependent relaxations to serotonin is high in epicardial and much lower in intramyocardial coronary arteries, that to endothelium-dependent relaxations to bradykinin is almost negligible in epicardial and completely absent in intramyocardial coronary arteries. The endothelium-derived relaxing factor distinct from nitric oxide is probably related to hyperpolarization. Prostacyclin does not contribute to endothelium-dependent relaxations in porcine coronary arteries. and its receptors are externalized under those conditions, the peptide is an unlikely candidate as mediator of the hypoxic contractions.4~-49 Indeed, while the response to hypoxia is rapid and transient, that to the peptide is slow and sustained.
Cyclo-oxygenase-dependent endothelium-derived contracting factor (EDCF2) Exogenous arachidonic acid evokes endothelium-dependent contractions in vessels of the rabbit and dog. These contractions are prevented by indomethacin indicating that a product of cyclo-oxygenase is involved ( Figure 5 ). 50, 51 In the human saphenous vein, acetylcholine and histamine evoke endothelium-dependent contractions; in the presence of indomethacin, however, endothelium-dependent relaxations are unmasked. The products of cyclo-oxygenase mediating the contractions are thromboxane A2 in the case of acetylcholine and endoperoxides in that of histamine. 52 Under certain experimental conditions, however, the amounts of vasoconstrictor prostaglandins released are not sufficient to explain the contractions. 32 Since activation of endothelial cyclo-oxygenase also generates superoxide anions, a contribution by the latter has to be considered. 53 Indeed, superoxide anions evoke contractions of the canine basilar artery; furthermore, superoxide dismutase prevents endothelium-dependent contractions in the rat basilar artery.54 Thus, not only thromboxane A2 and endoperoxides such as prostaglandin H2, but also superoxide anions can act as an endotheliumderived contracting factor ( Figure 5 ).
Endothelin
Endothelial cells release the 21 amino acid peptide endothelin ( Figure 5 ).55 There are three forms of the peptide: endothelin-1, endothelin-2 and endothelin-3.56 Endothelial cells appear to produce exclusively endothelin-1 although all Figure 5 The endothelium is a source of different contracting factors. Hypoxia leads to the production of a yet unidentified contracting factor. Products of cyclo-oxygenase such as thromboxane A2, prostaglandin H2 and superoxide anions constitute another factor which causes increases in tension. Endothelin as well as angiotensin II are also endothelium-derived contracting factors, since they are both produced by endothelial cells. (Source: Loscher TF, Richard Translation of the messenger RNA generates preproendothelin, which is converted to proendothelin and then to big endothelin. 57 The conversion of big endothelin to endothelin-1 by the endothelin converting enzyme is necessary for the development of full vascular activity of endothelin-1.58 The expression of messenger RNA as well as the release of the peptide is stimulated by thrombin, transforming growth factor r3, interleukin-1, epinephrine, angiotensin II, arginine vasopressin, calcium ionophore and phorbol ester. In addition, nitric oxide and prostacyclin as well as a factor derived from vascular smooth muscle cells inhibit the release of the peptide.
Endothelin-1 is a potent vasoconstrictor both in vitro and in vivo ( Figures 6 and 7) . The concentration evoking 50% of the maximal contraction is 10-100 times lower than for other contractile agonists.55,59 However, the circulating levels of endothelin-1 are very low suggesting that either little of the peptide is formed under physiological conditions due to the absence of Figure 6 In porcine intramyocardial resistance arteries, endothelin is much more potent than acetylcholine or serotonin in evoking contractions. Moreover, the capacity of the endothelium to antagonize contractions is less pronounced with endothelin than with the other agonists.
(Source: Tschudi Since oxidized low density lipoproteins (LDL) are present in atherosclerotic lesions, such alterations could be related to an interaction between the lipoproteins and the endothelium. 74 Indeed, oxidized LDL inhibit endothelium-dependent relaxations to acetylcholine in the rabbit aorta as well as to serotonin and to platelets in the porcine coronary artery (Figures 8 and 9 ).~s-~Ĩ n contrast, relaxations to arteries without endothelium to the nitric oxide donor SIN-1 are well maintained excluding a reduced responsiveness of vascular smooth muscle to EDRFs.
The inhibition of endothelium-dependent relaxations to acetylcholine is specific for the oxidized form of the lipoproteins; it is not induced by comparable concentrations of native LDL,. [75] [76] [77] Thus, substances present in the oxidized, but not the native form of the lipoproteins may mediate the effect. The lysolecithin concentration is much higher in oxidized than in native LDL.
Indeed, the effect of oxidized LD could be mimicked by incubation of the rabbit aorta with lysolecithin.75,78 However, in the porcine coronary artery, lysolecithin does not have an effect on endothelium-dependent relaxations Moreover, the substance is a relaxing factor in other preparations.79 Thus, oxidized LDL may exert its effect on the endothelium by activating a receptor distinct from the LDL receptor. Oxidized LDL bind to the scavenger receptor which is present on endothelial cells.8~~g1
Dextran sulphate is a competitive antagonist of modified LDL for the scavenger receptor.82 Incubation of porcine coronary arteries with dextran sulphate completely prevents the inhibition of endothelium-dependent relaxations by oxidized LDL. Thus, the lipoproteins impair the production of EDRFs by activating the endothelial scavenger receptor
In the porcine coronary artery, oxidized LDL inhibit endothelium-dependent relaxations to serotonin, but not to bradykinin. Since the same pattern of action is obtained with inhibitors of the production or the action of nitric oxide such as L-NG-monomethyl arginine, methylene Figure 7 In the human forearm, lovv concentrations of endothelin cause relaxation, vvhile higher concentrations evoke contraction. This increase in vascular resistance is prevented by the calcium antagonists verapamil and nifedipine; both drugs unmask relaxations to the peptide. (Source: Kiowski W, Luscher TF, Linder L, Buhier FR. Endothelin-1 induced vaso-constriction in man: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991; 83: 469-75.) blue and haemoglobin, the lipoproteins may specifically interact with the production of EDNO. However, nitric oxide synthetase does not seem to be inhibited, as L-arginine evokes a full relaxation when added on top of the inhibited response to serotonin in vessels treated with oxidized LDL. Furthermore, pretreatment with the amino acid normalizes the response to the monoamine in vessels treated with the lipoproteins. Thus, oxidized LDL may interact with the intracellular availability of L-arginine, either by inhibiting its release from intracellular stores or its synthesis (Figure 10 ).77
In coronary arteries obtained from hypercholesterolaemic pigs, endothelium-dependent relaxations to serotonin are inhibited, while those to bradykinin are fully maintained.83
As the same pattern of inhibition of endothelium-dependent relaxation to serotonin and bradykinin is obtained in arteries exposed to oxidized LDL, the reduced endotheliumdependent relaxations of hypercholesterolaemic arteries may be explained by the accumulation of oxidized LDL in the blood vessel wall.
Indeed, a decreased release of EDRFs accounts for the impaired endothelium-dependent relaxa- Basel: Birkh6user, 1991.) .) tions in hypercholesterolaemic porcine coronary arteries. 84 Furthermore, hypercholesterolaemic arteries relax to L-arginine, while the aminoacid does not affect the tone of normal arteries.85
Oxidized LDL not only inhibit endotheliumdependent relaxation, but also cause endothelium-dependent contraction. While the relaxations are inhibited even after the lipoproteins have been removed,75,77 the contractions are observed when the lipoproteins are present in the control solution. 76 In the porcine coronary artery, these contractions are prevented by inhibitors of EDNO indicating that the lipoproteins induce increases in tension by reducing the amount of the relaxing factor formed under basal conditions. The contractions are also prevented by catalase suggesting a role for hydroperoxides as inactivators of EDNO. 76 In line with that interpretation, both native and oxidized LDL have been shown to inactivate nitric oxide released from cultured endothelial cells. 86 In the rabbit femoral artery, oxidized LDL potentiate contractions to potassium chloride as well as to receptor-operated contractile agonists. In this preparation, the effect of the lipoproteins is independent of the endothelium and prevented by calcium antagonists indicating that it is related to an interaction with vascular smooth muscle cells.87
Oxidized LDL also induce the expression of messenger RNA for endothelin in cultured porcine aortic endothelial cells as well as the release of the peptide from the intact porcine aorta. 88 Thus, oxidized LDL inhibit endothelium-dependent relaxations and promote endothelium-dependent as well as endotheliumindependent contractions; the consequences are profound alterations in vascular tone leading to vasospasm and thrombus formation both of which are observed in patients with coronary artery disease.
Atherosclerosis
In porcine coronary arteries, established atherosclerosis further impairs endotheliumdependent relaxations to serotonin as compared to hypercholesterolaemic arteries and also reduces endothelium-dependent relaxations to bradykinin which are maintained in hypercholesterolaemia.83 However, endotheliumindependent relaxations to nitrovasodilators remain preserved under these conditions. Similarly, endothelium-dependent relaxations to acetylcholine in the rabbit aorta are progressively inhibited as the degree of fatty streak formation increases; only in severely atherosclerotic arteries endothelium-independent relaxations become impaired. 89 In iliac arteries obtained from monkeys fed an atherogenic diet, severe atherosclerosis develops, and endothelium-dependent relaxations to acetylcholine and thrombin are inhibited.9~ In coronary microvessels of the same species, neither intimal thickening nor plaque formation are detected by histological examination; however, changes in endothelium function similar to those occurring in conduit arteries are observed. 91 Thus, endothelial function is impaired in conduit as well as in resistance arteries of cholesterol-fed monkeys, while morphologic features of atherosclerosis are present only in large arteries of this species.
In atherosclerotic human coronary arteries obtained from transplant recipients, endotheliumdependent relaxations to substance P, bradykinin, calcium ionophore and aggregating platelets are attenuated. 92 Acetylcholine causes paradoxical vasoconstriction in these arteries. 93 The loss of relaxations to acetylcholine is tightly linked to risk factors for coronary artery disease such as cholesterol level, male gender, age and family history.94 While serotonin dilates normal human coronary arteries when infused intra-arterially, it induces paradoxical vasoconstriction in patients with coronary artery disease. This divergent effect is most likely related to a reduced formation of EDNO indicating that a dysfunctional endothelium is present in the coronary circulation in vivo. 95 The vasoconstriction to serotonin is more pronounced in patients with variant angina as compared to those with the stable form of the disease. 96 During later stages of atherogenesis not only the reduced formation of EDNO but also the concomitant release of vasoactive prostaglandins may contribute to the inhibition of endothelium-dependent relaxation. Alternatively, or in addition, intimal thickening may act as a functional barrier. In the rabbit aorta, this inhibition appears to be related exclusively to a functional barrier between the endothelium and the vascular smooth muscle due to atherosclerotic vascular disease while the production of EDNO is maintained or even augmented.97 Thus, impairment of the passage of endotheliumderived relaxing factors from the endothelium to vascular smooth muscle may importantly contribute to vascular dysfunction in atherosclerosis. It is possible that accumulation of LDL takes part in the development of this functional barrier due to the nitric oxide inactivating properties of the lipoproteins. 86 In severely atherosclerotic arteries, even the relaxing capacity of vascular smooth muscle becomes impaired.89 This may be related to the Figure 10 Proposed mechanism of action of oxidized LDL: oxidized LDL activate the endothelial scavenger receptor and interfere with the intracellular availability of L-arginine. The receptor-operated and Gi-protein mediated activation of the nitric oxide forming enzyme upon stimulation with serotonin (5-HT) does not seem to be affected by the lipoproteins. Endothelium-dependent relaxations to bradykinin (BK), as well as endothelium-independent relaxations to SIN-1, the active metabolite of molsidomine, are not inhibited by oxidized LDL. extensive formation of atherosclerotic plaques leading to fibrosis and calcification of the blood vessel wall.
Therapeutic implications
Nitrovasodilators relax arteries by a direct action on vascular smooth muscle cells.
Their effect is not reduced by the alterations in endothelial function occurring in hypercholesterolaemia and in atherosclerosis except at very late stages of the disease process; on the contrary, nitrovasodilators are more effective in arteries devoid of functional endothelial cells (Figure 11 ).98 In addition, SIN-1 reduces the endogenous nitric oxide production99; this effect is much less important in arteries in which formation of EDRF is already decreased. However, in severely atherosclerotic arteries, when the media becomes involved as well, relaxations to nitrovasodilators are also impaired, presumably because the atherosclerotic lesions attenuate the relaxing capacity of the arteries. 9
If LDL becomes more atherogenic after oxidation, then the use of an antioxidant should represent a promising therapeutic tool. Indeed, endogenous antioxidants such as ascorbate and tocopherol prevent the generation of highly atherogenic lipid hydroperoxides in plasma. 100 Probucol is a powerful antioxidant and very effective in preventing the oxidation of LDL, probably because it is transported in the plasma primarily within the lipoprotein fraction. Probucol inhibits the degradation of LDL in atherosclerotic lesions and decreases the progression of these lesions in atherosclerotic rabbits. 101 Since in that study the plasma cholesterol levels in the control animals were adjusted to the level of probucol-treated rabbits by appropriate doses of lovastatin, the beneficial effect of probucol can be attributed to its antioxidant action and is unlikely to be related to its cholesterol lowering effects. Interestingly, treatment of cholesterol-fed rabbits with probucol also preserves endothelial function. 102
Calcium channel blockers exert antiatherogenic effects which are not related to their blood pressure lowering effect nor to changes in lipoprotein levels. 103 Several mechanisms have been proposed to explain the antiatherosclerotic effects of calcium antagonists including inhibition of cell migration and cell proliferation as well as decreased deposition of matrix protein. io4 They also prevent endothelial hyperpermeability and suppress lipid accumu- Figure 11 1 Endothelium-derived nitric oxide reduces the potency of SIN-1, the active metabolite of molsidomine, in evoking relaxations of intramyocardial coronary resistance arteries, since L-NG-monomethyl arginine (L-NMMA) enhances the sensitivity to the nitrovasodilator. In line with that interpretation, relaxations of arteries without endothelium are not different in the presence or absence of L-NMMA. (Source: Tschudi M, Richard V, Buhler FR, Luscher TF. Importance of endothelium-derived nitric oxide in porcine coronary resistance arteries. Am J Physiol 1991; 260: H13-20,) lation, thereby reducing the passage as well as the subsequent deposition of lipoproteins in the vessel wall. They partially prevent the impairment of endothelium-dependent relaxations in cholesterol-fed rabbits; this effect may be related to the interaction of calcium antagonists with the metabolism of lipoproteins in the vessel wall.los
